Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2022-11-01 15:25:16
The CMD is a live event, open for physical attendance at Hotel Continental in
Oslo, Norway, and as a live webcast. It starts at 14.30 CET, and is expected to
last approximately two hours, including Q&A.
Speakers will be:
* Øystein Rekdal, CEO of Lytix
What makes Lytix' immuno-oncology technology platform stand out as unique?
* Niels Junker, Chief Physician at Herlev Hospital and investigator at the
ATLAS-IT-04 proof-of-concept study
Investigating the safety and efficacy of LTX-315 and adoptive T-cell therapy in
patients with advanced/metastatic soft tissue sarcoma - a pilot study.
* Aurélien Marabelle, Professor of Clinical Immunology, Université Paris Saclay
and an internationally recognized expert on intratumoral cancer treatment
Liver cancer: Current treatment modalities and how oncolytic molecules could
play an integral role in future liver cancer treatment.
* Stephen Worsley, CBO of Lytix
The commercial versatility of oncolytic molecules: What can LTX-315/401 bring to
the immuno-oncology table/offer to the pharmaceutical industry.
Registration, for physical or virtual attendance: Before November 21, 2022, at
14.30 CET: https://www.lytixbiopharma.com/news/events/register-for-event.html